Trillium Therapeutics Inc (TRIL)

[NY1972]

I said the same things when c90002, 621 and Huxxx were the only games in town.

[vinmantoo]

How many bios are targeting CD47? The slice for tril is getting smaller everyday.

You are quite wrong. So far, TRIL's CD47 blocker seems to be far better than the others.

[NY1972]

Pyrrhic victory for holders since 2016. I sold when Nic started 300 pt. P1. I wonder what could have happened to tril if gild did not pump billions into the CD47 space in time.

[LongRun8]

You're back!!

[NY1972]

How many bios are targeting CD47? The slice for tril is getting smaller everyday. I think the winner in this space will be bispecific mAb.

[jondoeuk]

Yes, an oral presentation for 621, and negative data would rarely be given such a slot.

[SweatpantKing]

Right after the presentation. Interesting choice.

[jondoeuk]

ASH Investor Call https://event.on24.com/wcc/r/2862177/A91BDB88D738527918C13E289B26CED7

[jondoeuk]

Same here. They also expect to identify the MTD/RP2D for both assets in 4Q to 1H 2021.

[Whalatane]

TRIL in Bloomberg this am

For Trillium investors that have stuck with its revival led by chief executive Jan Skvarka, the payout has been massive. The stock has surged 4,550% since Skvarka joined the company last September and is the top stock by a mile on Canada’s S&P/TSX Composite Index this year -- skyrocketing past tech behemoth Shopify Inc. and a bevy of gold miners by more than tenfold.

The next catalyst for the Cambridge, Massachusetts-based biotech firm will be updated results from a pair of cancer drugs at the American Society of Hematology meeting next month. Promising data have been the key driver of the stock’s surge and fresh results could spark a move higher, according to analysts.

Kiwi

[seschm]

I agree

[vinmantoo]

There is no way TRIL would take a $2.5 billion offer as so far TTI-621 and especially TTI-622 are performing better that the CD47 inhibitor from FTSV. The price would have to be closer to double what FTSV brought in.

[biocqr]

ALXO > impressive ORR vs SOC (pg 32)...

https://ir.alxoncology.com/static-files/bee60c4d-90dc-4991-a6d5-efdb01c393f8

ALX Oncology (Nasdaq: ALXO) is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system

[northern vortex]

A Gilead buy out would be a real long shot considering they bought out a company with a similar therapeutic earlier this year.

https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion

P.S. Why would $2.5bn be an appropriate value for TRIL when GILD paid $4.9bn for 47?

[fink]

There is your buy out partner. Figures.

I will assume a deal is already made once Trillium gains an FDA approval.,
This is a repeat of (MITI) Micromet.

In September 2020, the Company issued 2,297,794 common shares at a price of $10.88 per share to Pfizer Inc. in a registered direct offering. The gross proceeds from this offering were $25.0 million, before deducting offering expenses of $0.1 million.

[SweatpantKing]

I threw a little money at it at .70 so I'm just along for the ride. It's behind others like 47 and tgtx but I'm looking forward to the data coming out in a few weeks. Your valuation seems reasonable at this point. I'd like to start selling around 30 or so. I do think it could get a lot higher but that's a few years down the road.

[whytestocks]

JUST IN: $TRIL Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results

CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and o...

Read the whole news TRIL - Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results

[fink]

The wife threw this under my nose.

Is that like the cab driver asking about a stock?

I can see aGilead buying it out at the right time. $2.5B, maybe?
With a $1.3B market cap @$15.5 gives a little room to bank.

But how long till it scores an FDA approval and serious buy out eyes?

I don’t think Trillium has a sales force to even sell It. They will need a partnership or buy out.

I love the trend. Kind of addictive

[SweatpantKing]

I don’t know if it’s a leak but it’s worth a run up considering the data could be really positive.

[vinmantoo]

Looking forward to the updated data!

You have to wonder if the data is beginning to leak out given the nice rise today on somewhat higher than normal volume.

[SweatpantKing]

Looking forward to the updated data!

[jondoeuk]

ASH data on 621 and 622 https://ash.confex.com/ash/2020/webprogram/Paper136198.html https://ash.confex.com/ash/2020/webprogram/Paper136607.html

[Fress]

top picks:
Tril looks ready.

PDSB next generation T cell platform.

$TRIl

[chipboarder]

Absolutely correct....a few percent ownership and a seat on the Scientific Advisory Board to track the technology from the front seat! This is a Warren Buffett tactic ...buy a small position, follow it closely make a bigger investment when things are about to pop.

Pfizer is trying t beef up it’s oncology offerings and it’s less risky to purchase promising technology than to start from scratch.

Feels good to me.

[vinmantoo]

Market tanking big tome today and taking Biotech down with it. TRIL is no exception.

[whytestocks]

Just In: $TRIL Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors

CAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointme...

Find out more TRIL - Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors

[ANS414]

Anyone watching this morning? Not sure if it’s the news of the new BOD appointment or just following 47’s trajectory once reaching the $15 benchmark, but this morning’s activity is significant. The volume is there to support it, too.

[seschm]

Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells

https://www.nature.com/articles/s41467-020-18245-7

very interested to see if Tril gets any response in solid tumors, we should know next summer

[mr5874]

We’ve always had the comparative chart of FTSV to look at, and this chart here is starting to look awfully similar. Will be interesting to see where it ultimately ends up. Jan has been chumming the waters, that is obvious after this week‘s series of events. Can’t see how this doesn’t get gobbled up with the right offer, assuming the data continues to impress.

[vinmantoo]

This is obviously headed higher... I think we could see upper teens by ASH.

It certainly could be. If this wasn't a crazy election year I would be more confident. As it stands, there could be a lot of turbulence. I am considering selling some 5%-10% of my shares to bank some extra cash to take advantage of some down swings.

[mr5874]

This is obviously headed higher... I think we could see upper teens by ASH.

[vinmantoo]

Priced at $13

That sets the floor.

[LongRun8]

Priced at $13

[$treet $inatra]

awesome, congrats $$$$

[Fress]

My calls on Tril are up 300% this week

Long and strong and like to get the friction on.


$TRIL Forty seven has nothing on us
$PDSB next runner immunotherapy & infectious diseae T cell platform

[$treet $inatra]

TRIL keeps on running ~

[goarmy123]

$TRIL Ouchy.

[ClayTrader]

* * $TRIL Video Chart 09-09-2020 * *

Link to Video - click here to watch the technical chart video

[whytestocks]

BREAKING NEWS: $TRIL Trillium Announces Proposed Public Offering of Common Shares

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has c...

Read the whole news TRIL - Trillium Announces Proposed Public Offering of Common Shares

[$treet $inatra]

Good news here today $TRIL $$$$

[vinmantoo]

$25M equity investment from PFE

Jon,

That is really great news as it required a mere 2.2 million share offering to PFE, a trivial dilution. More importantly, it brings in the PFE Chief Science Office to help quide TRIL forward as it expands trials. That kind of expertise and close association with PFE is invaluable. It also gives PFE the inside track for a future larger equity stake or even a buyout down the road. Good times for TRIL investors.

[whytestocks]

BREAKING NEWS: $TRIL Why Trillium Therapeutics Stock Is on Fire Today

Shares of the clinical-stage immuno-oncology company Trillium Therapeutics (NASDAQ: TRIL) jumped by as much as 40% in pre-market trading Wednesday morning. The biotech's shares are rocketing higher today for two material reasons: Image source: Getty Images. Although Pfizer didn't exactly b...

Got this from TRIL - Why Trillium Therapeutics Stock Is on Fire Today

[jondoeuk]

I was going to add it, but ran out of time. Thanks

[jondoeuk]

$25M equity investment from PFE https://www.globenewswire.com/news-release/2020/09/08/2090474/0/en/Trillium-Therapeutics-Announces-25-Million-Equity-Investment-From-Pfizer-Inc.html

[vinmantoo]

Here is a news release.

http://www.globenewswire.com/news-release/2020/09/08/2090436/0/en/Trillium-Therapeutics-Announces-Updated-Data-From-Its-Ongoing-TTI-622-and-TTI-621-Dose-Escalation-Studies.html

[jondoeuk]

The company will host a live conference call and webcast at 5:30 p.m. ET today to discuss this clinical data update. The conference call may be accessed by [phone] and with conference ID 7695694. The webcast may be accessed on Trillium's Events and Presentations page at https://ir.trilliumtherapeutics.com/events-and-presentations or at https://event.on24.com/wcc/r/2645255/C032FE41D7E0F23D4D47E9DFA2D71982 The archived webcast will be available on Trillium’s website for 30 days following the call.

[biotech_researcher]

Up strong AH

[mr5874]

All valid points, but I would imagine that if ASH data is as promising as what most TRIL researchers/holders believe, the offering would be eaten up quickly with minimal impact. I have a gut feeling that we are headed higher... but the market is weird and so is everything here in the US right now.

[vinmantoo]

With the likelihood of PRs turning to CRs with the added assessment time, this historical "cult" stock could become much more than speculative. It could have the most solid science of the CD47 space.

FTSV already proved that anti-CD47 was a viable anti-cancer approach and that is when I dramatically increased my shares of TRIL at prices from $0.45 through $2. The early TRIL data suggest TTI-621 and TTI-622 will be at least as good but likely superior. For me now I am deciding when to sell a bit to get back some if not all my investment so that I am playing with house money. I came close to doing that yesterday. Depending on how the stock goes as ASH draws closer, I may do it before ASH. I learned the hard way that it is better to make less than I could have than to lose more than I am comfortable with. Besides, if there is a nice run up, often there is a drop after as the old sell the news kicks in. That could provide a buying opportunity with the cash I accumulated by the pre-ASH selling.

You also have to consider that TRIL might issue another offering if the price rises again after ASH, say to generate another $100 million+. Can't have too much money on hand. We will see.

[mr5874]

Beautiful movement the past couple of weeks. Chart continues to look spectacular, as we move into double digits. Still believe TRIL is undervalued compared to its peers (especially ALXO). Now that we have another player gaining attention due to relatively recent IPO, we have another valuation gap comparison. CD47 will be white hot this coming ASH. With the likelihood of PRs turning to CRs with the added assessment time, this historical "cult" stock could become much more than speculative. It could have the most solid science of the CD47 space.